VNZ/TEZ/D-IVA
Phase 3Small molecule
Vertex PharmaceuticalsVNZ/TEZ/D-IVA is one of 49 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
105 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Mycobutin
PfizerPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Verapamil Hydrochloride
Mylan Pharmaceuticals IncPhase 3
Hyperpolarized Xenon-129
TThunder Bay Regional Health Research Institute
Phase 3
Initiation of CFTR Modulator
CChildren's Hospital Medical Center, Cincinnati
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Statin1 trial
Cystic Fibrosis1 trial
Adult1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VNZ/TEZ/D-IVA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company